Home » Company » Team Bios » David Schuetz, RPh

David Schuetz, RPh

Senior Consultant

Mr. Schuetz has been working in pharmacy for over thirty years. He has held headquarter management positions with Giant Eagle Pharmacy (Pittsburgh) for eleven years prior to joining PHSL in 2001. His diverse professional experience includes independent and chain retail pharmacy operations, mail service pharmacy, pharmacy network contracting, prescription claims processing, pharmacy auditing, account management, intervention program development, and pharmacy training.

Dave’s areas of expertise are pharmacy practice management, electronic ordering systems operations, testing, training, documentation and deployment. He also specializes in pharmacy database and drug file management, and serves as subject matter expert in pharmacy data warehousing.

Dave received a Bachelor of Sciences Degree in Pharmacy from Duquesne University and is presently an active member of the National Council of Prescription Drug Programs (NCPDP) and the National Association for Chain Drug Stores (NACDS).

February 2023 Question of the Month

Do you feel like your organization understands the FDA’s Draft Guidance for Industry on Drug Importation?

We have reviewed the guidance and are taking a watch and wait approach: 75%

We have reviewed the guidance and are taking proactive steps to act on it: 25%

We have reviewed the guidance but do not feel like it will impact our organization: 0%

Not familiar/We have not reviewed the guidance: 0%

January 2023 Question of the Month

How will payers manage reimbursement of multiple interchangeable biosimilars?

MAC reimbursement: 10%

Generic non-MAC reimbursement rate: 10%

Brand reimbursement rate: 40%

Specialty drug specific rate: 40%

Average Sales Price (ASP): 0%

Average Manufacturer Price (AMP): 0%

National Average Drug Acquisition Cost (NADAC): 0%

December 2022 Question of the Month

In which area could you or your company most benefit from additional training?

Biosimilars and interchangeability requirements: 46.1%

Dynamics that drive PBM and health plan decisions: 15.4%

Various hurdles a prescription must clear before being dispensed: 15.4%

Changing 340B landscape: 15.4%

Flow of funds and prescriptions through the pharmacy channels: 7.7%

Pharmacy chain initiatives and strategy updates: 0%